Evidence map›Paper›PMID 35432870›Full record

ArticleChemical science2022

The convergent total synthesis and antibacterial profile of the natural product streptothricin F.

Matthew G Dowgiallo, Brandon C Miller, Mintesinot Kassu, Kenneth P Smith, Andrew D Fetigan, Jason J Guo, James E Kirby, Roman Manetsch

Abstract read
In one paragraph

Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthew G DowgialloDepartment of Chemistry and Chemical Biology, Northeastern University Boston MA USA r.manetsch@northeastern.edu.ORCID https://orcid.org/0000-0001-9414-6374
Brandon C MillerDepartment of Chemistry and Chemical Biology, Northeastern University Boston MA USA r.manetsch@northeastern.edu.ORCID https://orcid.org/0000-0002-5421-0113
Mintesinot KassuDepartment of Chemistry and Chemical Biology, Northeastern University Boston MA USA r.manetsch@northeastern.edu.
Kenneth P SmithDepartment of Pathology, Beth Israel Deaconess Medical Center Boston MA USA.
Andrew D FetiganDepartment of Chemistry and Chemical Biology, Northeastern University Boston MA USA r.manetsch@northeastern.edu.
Jason J GuoDepartment of Chemistry and Chemical Biology, Northeastern University Boston MA USA r.manetsch@northeastern.edu.
James E KirbyDepartment of Pathology, Beth Israel Deaconess Medical Center Boston MA USA.ORCID https://orcid.org/0000-0003-0392-4500
Roman ManetschDepartment of Chemistry and Chemical Biology, Northeastern University Boston MA USA r.manetsch@northeastern.edu.ORCID https://orcid.org/0000-0001-7038-6867

Funding

Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class AntimicrobialsR01AI157208 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, MANETSCH, ROMAN · 2020 to 2024
$3.9M
Development of Streptothricin Class Antimicrobials as Novel TherapeuticsR21AI140212 · NIAID · NORTHEASTERN UNIVERSITY · PI KIRBY, JAMES E, MANETSCH, ROMAN · 2019 to 2020
$467k
Identification and Characterization of Novel Antimicrobial Adjunctives to Restore Susceptibility to Carbapenem Resistant EnterobacteriaceaeF32AI124590 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SMITH, KENNETH PATRICK · 2017 to 2019
$175k
NIAID NIH HHS F32 AI124590NIAID NIH HHS R01 AI157208NIAID NIH HHS R21 AI140212
6 · The paper itself

Abstract

A convergent, diversity-enabling total synthesis of the natural product streptothricin F has been achieved. Herein, we describe the potent antimicrobial activity of streptothricin F and highlight the importance of a total synthesis that allows for the installation of practical divergent steps for medicinal chemistry exploits. Key features of our synthesis include a Burgess reagent-mediated 1,2-

Identifiers

PMID35432870
PMCPMC8943883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.